BRÈVE

sur Isomorphic Labs

Isomorphic Labs and MSD Announce Strategic Research Partnership

On November 19, 2026, Isomorphic Labs, a company focused on AI-driven drug design, and MSD, known as Merck & Co., Inc. in the USA, revealed a joint research initiative. This collaboration combines Isomorphic's AI capabilities in drug discovery with MSD's vast proprietary data and expertise.

The partnership aims to develop therapeutic small molecule candidates for an important oncology target. Isomorphic will deploy its IsoDDE drug design engine, using select data from MSD. MSD will handle preclinical and clinical activities, alongside manufacturing and commercialization.

Isomorphic will receive an upfront fee and could earn milestone payments and royalties. The firm also has an option to co-fund development activities. Key leaders from both companies expressed excitement about this collaboration, which highlights the synergy of advanced AI and pharmaceutical expertise.

R. P.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Isomorphic Labs